Bristol’s oral drug to treat Crohn’s disease fails remission test
HQ Team March 29, 2024: Bristol Myers Squibb’s final stage clinical trials for its Zeposia oral drug, to treat moderate to severe Crohn’s.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team March 29, 2024: Bristol Myers Squibb’s final stage clinical trials for its Zeposia oral drug, to treat moderate to severe Crohn’s.
HQ Team March 20, 2024: Bristol Myers Squibb, a New Jersey-based drugmaker, announced it has met its primary goal of improved overall survival.
HQ Team December 23, 2023: Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio,.
HQ Team December 12, 2023: Bristol Myers Squib will pay a total of $8.4 billion to SystImmune Inc., the US arm of Chinese.
HQ Team October 9, 2023: Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, will acquire Mirati Therapeutics for $5.8 billion through.
HQ Team September 28, 2023: Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by.